Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Hint: It’s not a bad investment idea.
The stock prices of Eli Lilly and Novo Nordisk have been diverging over the past year. While Eli Lilly's shares have risen by 41%, Novo Nordisk's have fallen by 15%. Both pharmaceutical giants are in the lead of the rapidly expanding weight loss drug market, and they both have promising Phase 3 clinical candidates. However, they face potential challenges such as intensified competition in the weight-loss sector.
Assuming equal investment of $10,000 in both stocks, a possible future value of this investment by the end of 2027 can be estimated. For Eli Lilly, the stock's price-to-sales ratio could decrease from its current 14.9 to 14.2, yielding a potential gain of around 10.91%. This would result in a $5,000 investment growing to approximately $5,546.
Similarly, for Novo Nordisk, the stock's price-to-sales ratio may increase from 3.56 to 4, leading to an expected gain of around 13.67%. This would cause the $5,000 investment in Novo to swell to approximately $5,684.
Based on these projections, if $10,000 were divided equally between Eli Lilly and Novo Nordisk, the combined investment could potentially be worth $11,230 by the end of 2027. However, it's essential to note that there is considerable uncertainty in stock market projections, and any gains should be viewed as a long-term investment rather than a short-term windfall.
Nonetheless, based on their strong financial performance and promising pipelines, Eli Lilly and Novo Nordisk remain attractive options for healthcare investors in the long run.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.